Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Journal of Immunotoxicology|December 10, 2024
Type 2 responses determine skin rash during recombinant interleukin-2 therapyCharline Sommer, Vanessa Neuhaus, Patricia Gogesch, et al.Journal of Immunotoxicology|December 10, 2024
Revival of recombinant IL-2 therapy - approaches from the past until todayLuise A Roser, Charline Sommer, Samira Ortega Iannazzo, et al.European Journal of Immunology|March 2, 2024
Interleukin-2-induced skin inflammationCharline Sommer, Jarish N Cohen, Susann Dehmel, et al.Respiratory Research|January 4, 2024
Age-dependent inflammatory response is altered in an ex vivo model of bacterial pneumoniaCharline Sommer, Stella Marie Reamon-Buettner, Monika Niehof, et al.Clinical Immunology (Orlando, Fla.)|July 1, 2024
Bridging therapy-induced phenotypes and genetic immune dysregulation to study interleukin-2-induced immunotoxicologyCharline Sommer, Sophie Jacob, Tonia Bargmann, et al.Frontiers in Cellular and Infection Microbiology|September 9, 2022
Competitive fitness of Pseudomonas aeruginosa isolates in human and murine precision-cut lung slicesNina Cramer, Marie Luise Nawrot, Lion Wege, et al.Journal of Immunotoxicology|April 5, 2024
IL-2-mediated hepatotoxicity: knowledge gap identification based on the irAOP conceptLuise A Roser, Christina Sakellariou, Malin Lindstedt, et al.Respiratory Research|November 15, 2025
Regulation of T cell tissue residency and activation in human PCLSTonia Bargmann, Charline Sommer, Lena Stowasser, et al.Frontiers in Immunology|August 27, 2025
An explorable model of an adverse outcome pathway of cytokine release syndrome related to the administration of immunomodulatory biotherapeutics and cellular therapiesAlexander Mazein, Oxana Lopata, Kristin Reiche, et al.European Journal of Immunology|September 15, 2025
Activation of CD8⁺ T Cells in the Human Ex Vivo Lung Tumor Microenvironment Using Anti-CD3/CD28 and NivolumabTonia Bargmann, Sebastian Konzok, Renato Liguori, et al.Pageof 2